CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes mellitus
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Abatacept (Primary)
- Indications Glucose intolerance; Glucose metabolism disorders; Type 1 diabetes mellitus
- Focus Therapeutic Use
- 01 Dec 2023 This trial has been completed in Finland, according to European Clinical Trials Database record.
- 03 Jul 2023 Status changed from active, no longer recruiting to completed.
- 13 Apr 2022 Planned End Date changed from 1 Nov 2021 to 30 Nov 2024.